Skip to Main Content

Paper Details

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Neurol Ther
17
2023
Author NameAffiliation
Djillali AnnaneUniversity of Versailles
  • 1 - 1

Datasets

Release 1.2